This study investigated the association of age with CD4+ cell counts of HIV patients receiving antiretroviral treatment (ART) over a 4 year period. Data were collected from 126,672 previously treatment-naïve patients in 4 Sub-Saharan African nations. The baseline CD4+ count was measured at onset of ART and at 6-month intervals thereafter. The predictor variable was the age at initiation of therapy with ages grouped in five 10-year ranges: 20-29, 30-39, 40-49, 50-59, and 60 and over. The following 8 baseline covariates were also noted: sex, WHO stage, functional status, active TB infection, active cryptococcal disease, active P. jiroveci pneumonia, other active opportunistic infections, and ART regimen. The resulting dataset includes 466,482 repeated CD4+ count measurements with demographic and other patient-related characteristics.
In 2015 the World Health Organization (WHO) eliminated CD4 restrictions for initiating antiretroviral therapy (ART) for people living with HIV (PLHIV) in developing countries. However, the success of therapy is also dependent upon additional health and demographic characteristics of HIV patients at the time they enroll in care. This study investigated pre-ART (time between enrollment and initiation of ART) factors associated with transition to therapy. Data was compiled from a review of 195,011 records of ART-naïve adults enrolled in HIV care and treatment facilities supported by AIDSRelief in Kenya and Tanzania. The outcome variable was transition out of pre-ART care by one of 4 mutually exclusive modes: started ART, died before ART initiation, lost to follow-up (LTFU), and transferred to another facility. The following baseline covariates were analyzed for their relevance to the mode of transition: sex, age at enrollment, CD4 count at enrollment, presence of tuberculosis at enrollment, presence of cryptococcal disease at enrollment, presence of other active opportunistic infections, and year of enrollment in care. The dataset includes demographic data and clinical measures.
This dataset was used to support a study investigating potential connections between mental health symptoms and biomarkers of inflammation in HIV infected subjects. Data was collected from 407 HIV-positive patients on antiretroviral therapy in the Dar es Salaam, Tanzania area from March to May of 2018. Data was collected though a survey that utilized the World Health Organisation's STEPwise approach for noncommunicable diseases surveillance as well as through anthropometric measurements, review of medical records, blood pressure assessments, and biochemical assessment of biomarkers in blood samples.
This study analyzed samples from 73 healthy donors and 81 individuals with HIV, divided into Natural Viral Suppressors (NVS), untreated non-EC patients (UP), and treated patients (TP). Samples were collected from various sources and subjected to serological, phenotypic, and virological assessments. Peripheral blood mononuclear cells (PBMCs) were isolated, CD4+T cells were stimulated, and flow cytometry was used to measure CCR5 and CXCR4 expression. Viral stocks were prepared from infectious molecular clones (IMCs), and virus growth kinetics were assessed. Immunophenotypic studies, cytokine quantification, and gene expression analyses were conducted.